issues with glp 1 drugs GLP-1 Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH The GLP-1 revolution: What UAB

Potential implications of the FDA approval of semaglutide for overweight and obese adults in the United States

Additional file 1: Fig S14)

GLP-1 ist ein Darmhormon aus der Familie der Inkretine und hauptschlich dafr bekannt, die Insulinsekretion in Abhngigkeit vom Blutzuckerspiegel zu stimulieren

GLP-1 drugs may help with appetite and weight reduction, but they may also create clinically meaningful nutritional side effects, especially in patients with poor baseline diet quality, prolonged use, gastrointestinal side effects, or rapid weight loss

Raz I., Hanefeld M., Xu L., et al., Efficacy and Safety of the Dipeptidyl Peptidase4 Inhibitor Sitagliptin as Monotherapy in Patients With Type 2 Diabetes Mellitus, Diabetologia 49 (2006): 25642571

Thus, shared decision-making between surgical, anesthetic, and medical teams is essential to balance risks and benefits [111]